<DOC>
	<DOCNO>NCT00291694</DOCNO>
	<brief_summary>To assess effect twelve month celecoxib administration evaluate breast tissue needle aspiration , determine cell growth slow .</brief_summary>
	<brief_title>Protocol Women Increased Risk Developing Breast Cancer</brief_title>
	<detailed_description>A blind randomize study celecoxib woman high risk develop breast cancer . Subjects take twelve month drug/placebo . At baseline twelve month subject random periareolar fine needle breast aspiration assess epithelial cell growth marker risk . Baseline twelve month serum sample also assess hormone growth factor may associate breast cancer risk . Mammograms baseline twelve month also assess breast density change .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>woman high risk breast cancer old 18 year anticoagulant mark breast tenderness pregnant within twelve month breast feeding/childbirth</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>breast atypia</keyword>
	<keyword>double-blind randomize clinical trial</keyword>
	<keyword>RCT</keyword>
	<keyword>celecoxib</keyword>
	<keyword>COX-2 inhibitor</keyword>
	<keyword>placebo</keyword>
	<keyword>high risk breast cancer</keyword>
	<keyword>breast epithelial hyperplasia</keyword>
	<keyword>ki-67</keyword>
	<keyword>chemoprevention</keyword>
</DOC>